ProCE Banner Activity

SWOG S1826: Nivolumab-AVD vs BV-AVD in Older Patients (Aged ≥60 Years) With Advanced Stage Classic Hodgkin Lymphoma

Conference Coverage

Nivo-AVD demonstrated improved PFS and EFS rates and better tolerability vs BV-AVD in patients aged ≥60 years with advanced classic Hodgkin lymphoma in a subset analysis of the phase III SWOG S1826 study.

Released: December 14, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AbbVie Inc., AstraZeneca, Daiichi Sankyo, Inc., Merck Sharp & Dohme LLC, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, and Seagen Inc.

AbbVie Inc.


Daiichi Sankyo, Inc.

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Regeneron Pharmaceuticals, Inc

Seagen Inc.